{"disease":{"id":"proportion-of-patients-with-a-sustained-virological-response-serum-hbv-dna-20-iu-ml-at-week-48","name":"proportion of patients with a sustained virological response serum hbv dna 20 iu ml at week 48"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03236610","title":"Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Uijeongbu St. Mary Hospital","has_results":false},{"nct_id":"NCT03236584","title":"Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"Uijeongbu St. Mary Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}